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ABSTRACT:  
Artemisinin is an antimalarial compound found in Artemisia annua at about .01-.1% DW. 
This in combination therapy is the most potent treatment we have against the parasite 
Plasmodium falciparum, curing even cerebral malaria.  
  
Brassica oleracea (Kale) has a large amount of carotenoids, a 40 carbon molecule, whose 
basis is 10 carbon monoterpenes. In this project we used A. tumefaciens to insert 
genes into Brassica oleracea that code for enzymes that produce farnesyl diphosphate 
and amorpha 4, 11-diene as well as a cytochome P450 that catalyzes multiple oxidations 
of intermediates. Through this we hope to show that the production of the precursor for 
artemisinin in the form of artemisinic acid is possible in larger quantities than they occur 
in A. annua. 
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INTRODUCTION: 
A sesquiterpene (a group consisting of C15H24) known as artemisinin is taken 
from the plant Artemisia annua. This chemical is used for anti-malarial treatment world 
wide. The most successful form of this treatment, is artemisinin-based combination 
therapies(ACTs)
1
. A second use that has been found is possibly the treatment of cancer. 
Artemisinin appears to be cytotoxic to cancer cells, having effects on cell proliferation 
and angiogenesis. One of the problems with this compound is that it occurs in extremely 
low quantities naturally, making up 0.01-1% of the plant’s dry weight. 
Artemisinin, a terpenoid, is an end result of complex series of reactions starting 
from the use of acetyl-coenzyme A (Acetyl CoA)
2
.  Terpenoids are one of the largest 
families secondary metabolites found in plants. A secondary metabolite is a compound 
not directly used in photosynthesis or respiratory metabolism
3
. Monoterpenes are found 
mostly in plants. They are used for many things ranging from being used to create 
commercial flavors  and scents
4
. Acetyl-CoAis formed in the metabolic breakdown of 
carbohydrates and fatty acids. Three acetyl-CoA molecules are condensed in a two step 
reaction to hydroxymethylglutanyl-CoA which is then reduced to mevalonic acid. 
Mevalonic acid then undergoes a two step phosphorylation consuming two ATPs to form 
a six carbon mevalonic acid pyrophosphate. A carboxyl group is then removed resulting 
in a five carbon compound, isopentyl pyrophosphate (IPP) and its isomers. The 
biosynthesis of terpenes uses one of each of these molecules and condenses them to form 
a 10 carbon unit, geranylpyrophosphate (GPP). Additional groups can be added in the 
same head to tail method to form increasingly larger groups. The 15 carbon intermediate 
formed by this is called farnesylpyrophosphate (FPP) and is the fundamental building 
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block for the formation of artemisinin. The formation of FPP occurs in the cytosol along 
with resulting triterpenes and further 15 carbon additions. A similar pathway also occurs 
in the plastid, but entirely avoids the mevalonic acid pathway. The plastidial pathway 
utilizes Pyruvate and Glyceraldehyde 3-phosphate as its starting compounds rather than 
Acetyl-CoA. The two pathways have been shown to have some amount of interaction
5,6
 
most notably with IPP. Farnesyl diphosphate synthase (FPS) is utilized in the conversion 
of IPP to FPP. FPP is converted into amorpha-4, 11-diene via catalysis by amorphadiene 
synthase (ADS)
7
.  
Cytochrome P450s are a large superfamily of proteins
8
 responsible for the 
metabolizing of drugs, as well as pollutants, steroids and other compounds. CYP71AV1, 
is responsible for catalyzing the next few steps of the pathway, yielding artemisinic 
alcohol, then taken to artemisinic acid
1
.  Artemisinin is thought to form in the glandular 
secretory trichomes (GSTs). These appear as tiny hairs, and can either secrete or contain 
a fluid, although artemisinin has been found in transformed roots as well
9
. Transformed 
roots are the result of DNA is recombining with host genome added via a vector such as 
Agrobacterium rhizogenes, and is then replicated along with the rest of the genome14. 
Plants that have been transformed with this bacteria have what is known as “hairy roots”. 
Artemisinin has been shown to accumulate in highly specialized glandular tissues in these 
roots, and is not normally detectable in wild type plants
10
. mRNA has been extracted 
from GSTs found on leaves. This allows us to extract the cDNA and amplify it via 
reverse transcriptase-polymerase chain reaction (RT-PCR).  
For years science has tried to find a way to synthesize artemisinin in large 
quantities. While scientists have been successful in chemically synthesizing artemisinin, 
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we still do not completely understand the complex method by which it is formed in vivo, 
and the yields are still low. There are some plants with a naturally high amount of 
carotenoids. These come from the fundamental building block of isopentyl 
pyrophosphate (IPP). This compound is a precursor for all terpenoids. What we endeavor 
to do is to genetically modify Brassica oleracea (kale) to produce artemisinic acid from 
the large amount of precursors (IPP), the plant naturally produces in the plastid.  
Artemisinin has a long history of use to battle illness. Artemisia annua has been 
mentioned in Chinese writings as far back as 340 B.C. for treatments of fevers. In the 
middle of the last century the Chinese government, looking for a cure for malaria started 
reviewing these old texts. As a result they came across qinghaosu, widely known as 
artemisinin. Since its isolation, various other treatments for malaria have been found 
such as: chloroquine, doxycycline, sulfadoxine-pyrimethamine (Fansidar®), mefloquine 
(Lariam®), and atovaquone-proguanil (Malarone®)11 Multi-strain drug resistance of 
Plasmodium falciparum is becoming far more of a problem in recent years12. One 
constant treatment that appears to work, even in the case of drug resistant strains is a 
combination therapies utilizing artemisinin
3
.  
There are a few proposed mechanisms of action for the effects of artemisinin on 
the malarial parasite Plasmodium falciparum. The first is that it interfs with a 
sarcoplasmic/endoplasmic reticulum Ca
2+
-ATPase (SERCA). The SERCA is responsible 
for maintain calcium ion concentrations needed for things such as calcium mediated 
signaling and some post-translational protein modifications, as well as protein folding. It 
has been shown that this targeting by artemisinin is so specific that even at higher 
concentrations (50µM) it doesn’t affect other transporters, this includes the non-SERCA 
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Ca
2+
-ATPase PfATP4. Artemisinin is thought to bind in the same region as a known 
SERCA Ca
2+
-ATPase inhibitor called thapsigargin (Tg). This was experimentally 
supported by application of both thapsigargin and artemisinin and observing a decrease in 
artemisinic activity. When the artemisinin binds to the protein using hydrophobic 
interactions it leaves the peroxide bridge exposed which is then reduced via a Fenton (fig 
1) reaction leaving a reactive oxygen species (ROS) this results in enzymatic deactivation 
and the death of the parasite. It has been shown in vitro that artemesinin is sterically 
sensitive. When smaller sidechains are replaced there is a large decrease in effective 
activity. This seems to indicate that artemisinin is activated after binding to a highly 
specific site. This is supported by studies of a single amino acid mutation of PfATP6 in X. 
laevis oocytes. The change of Leu263 alters the electrostatic interactions and prevents the 
binding of artemisinin to the protein
13
.  
 
Fe2+ + H2O2 ---->  Fe
3+ + .OH + OH- 
Fe3+ + H2O2 ---->  Fe
2+ + .OOH + H+ 
  (fig 1). A Fenton reactions where two different species of radicals are produced. 
 
Another possible effect is the activation of artemisinin by transition metals in the 
mitochondria, causing the production of reactive oxygen species. The creation of these 
oxygen species depolarizes the mitochondrial membrane and causes the loss of 
membrane potential negatively impacting the cell’s ability to produce pyrimidine; a 
necessity for the production of RNA and DNA
14
.  
There are several methods of producing artemisinin. The way that most 
commercial artemisinin is produced is from plants grown in a field. The problems with 
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this are the same that all field grown plants face. There are droughts, fungi, bacterial and 
insect impacts, all of which could affect the outcome of the final product to be used 
medicinally. It has been shown that the possibility exists to synthesize artemisinin. It is a 
ten step stereo-selective process, but is costly and has very low yields. Artemisinin 
biosynthesis has been studied in different parts of the plant A. annua that biosynthesis of 
artemisinin was studied in, including callus, suspension cells, shoots, and hairy roots. 
Different techniques were utilized to influence artemisinin production, ranging from 
supplementation with hormones, to increased ratios of nitrate to ammonia. Other 
techniques compared looking at the difference in the synthesis from autoclaved media to 
filter sterilized media to alterations in the sugar that was used. Light and the wavelength 
of the light in addition to the temperature were found to be factors that contributed to 
artemisinin production as well
15
.  
It has been shown that overexpression of isopentyl transferase (ipt) elevates 
cytokinin levels in transgenic plants, and in this case, elevating artemisinin by 30-70% 
when compared to the control
15
. 
Another method for producing artemisinin was to use bacteria instead of plants. 
The model system used for this was E. coli. This research started by creating the 
mevalonate-dependant pathway in E. coli. Researchers enhanced the bacteria’s natural 
production of IPP by taking all the enzymes necessary to synthesize FPP for the 
isoprenoid pathway from S. cerevisiae and expressing them in the E. coli. This was to 
take the large amounts of the precursor, acetyl-CoAand turn it into FPP. This pathway 
was coupled with an ADS pathway to produce  amorpha-4, 11-diene. Artemsinin was not 
produced, however the researchers believe that the biochemical pathway could be 
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extended to produce artemisinic acid
16
. This has been achieved in engineered yeast in 
comperable amounts to A. annua, however growth occurs in a matter of days.  
 The Covello group, studying compartmentalization and regulation dealing with 
terpene biosynthesis have found that they could obtain a larger quantities of of they 
coupled the overexpression of taxadiene synthase with an inducible transcription system 
in Arabidopsis. In plants they demonstrated that larger amounts of terpenes are produced 
in the plastid stating that cytosolic production is highly regulated
4
. Terpenes are a highly 
volatile compound
2
 and easily evaporate. Given that the cytosol is less contained that the 
plastid, we hypothesize that the difference in accumulation is not because the process is 
highly regulated in the cytosol, but escapes from the cytosol more easily. Below is a 
proposed method of some of the pathways for the theoretical biosynthesis of Artemisinin. 
9 
 
 
10 
 
 
MATERIALS AND METHODS: 
 
DNA Mini-Prep: 
 
A single bacterial colony was transferred into 2mL of LB medium containing 25μg/mL of 
kanamycin in a loosely capped 15mL tube. The culture was incubated overnight at 37
o
C 
with vigorous shaking. After 24 hours 1.5mL of the culture was transferred into a 
microfuge tube and centrifuged for 30 seconds. The medium was removed leaving only 
the bacterial pellet, which was resuspended in 100μL of ice cold GTE solution by 
vigorous vortexing. 200μL of freshly prepared .2M NaOH and 1% SDS solution (on ice) 
were then added. The tube was mixed by rapid inversion 5 times to make sure the entirety 
of the contents came in contact with the solution. 150μL of ice cold 5MKOAc solution 
was then added and stored on ice for 5 min. The tube was centrifuged and the supernatant 
transferred into a new tube. 1 volume of phenol chloroform was added and again 
centrifuged for 5 minutes. The the layer was transfered to a new tube. The dsDNA was 
precipitated using 2 volumes of ethanol and put into the –80oC freezer for 15 minutes. 
The mixture was allowed to stand at room temperature for 2 minutes before centrifuging 
for 15 minutes and removing the supernatant. The nucleic acids were redisolved in 30μL 
of TE (pH 8.0) containing 1μL RNAse and incubated at 37oC for 30 min.  
 
 
 
Preparation of Competent Cells: 
2 tubes of 5mL ½YEP media containing 50μL/mL of rifampicin were prepared and 
inoculated from a glycerol stock of Agrobacterium tumefaciens and shaken at 28oC. 24 
hours later they were used to inoculate a culture of 500mL ½YEP again incubated 
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overnight with shaking. Cultures were checked 24 hours later OD600>.6. The cultures 
were transferred to the pre-chilled sterile 450mL centrifuge tubes and centrifuged at 2700 
x g for 5min at 4
o
C. From this point on all work was conducted at 4
o
C. The supernatant 
was removed and discarded. The pellet was re-suspended in 100mL of pre-chilled 
glycerol (not vortexed). The suspension was centrifuged at 2700 x g for 5min at 4
o
C. The 
supernatant was discarded and the pellet resuspended in 5mL of ice-cold 10% glycerol 
(not vortexed). The suspension was transferred and combined into new 35mL centrifuge 
tubes. The 450 mL tubes were rinsed twice with 5mL of 10% glycerol and this was also 
combined with the suspension. These were centrifuged at 2700 x g for 5 min at 4
o
C. The 
supernatant was removed and the pellet was re-centrifuged for another minute to remove 
as much fluid as possible. A volume equal to the pellet of ice-cold 10% glycerol was 
added (about 1.5mL) and the pellet was re-suspended. The suspension was split in 40 μL 
aliquots and frozen overnight at –20oC then transferred to –80oC. 
 
Electroporation: 
DNA prepared in the mini-prep was put on ice as well as the electroporation cuvettes and 
the previously prepared competent cells. The competent cells were quickly hand thawed 
then put back on ice. 2 μL of miniprep DNA was put into a tube containing 20 μL of 
competent cells. They were mixed by tapping. The electroporator was set to a capacitance 
of 330, High Ω, charge rate of fast, and the voltage booster was set to 4kΩ. Ice was put 
into the chamber of the electroporator. DNA cell mix was put into the cuvettes without 
bubbles, and the apparatus was charged to 4V. After successful discharge the cells were 
incubated for 1-2 hours on LB media at 30
o
C, after which it was spread evenly onto an 
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LB plate and incubated overnight at 28
o
C. Transformants were selected for using 
kanamycin. 
 
Medium Quick References: 
All at pH 6.0 
 
-MS media 
 - Murashige & Skoog salts 
 
-Basal Medium 
 -MS medium, vitamins, 20g/L sucrose, 7g/L phytagel 
 
-Shoot outgrowth Medium 
-Basal Medium +40 mg/L adenine hemisulfate, 500mg/L polyvinylpyrrolidone, 
1μg/L BAP 
 
-Germination Medium 
 -MS medium set at 10g/L of sucrose, 7g/L phytagel 
 
-Callus Inductin Medium 
 -Basal Medium, 3mg/L BAP, .5mg/L silver Nitrate, .2 mg/L NAA, .01mg/L GA3 
 
-Root Induction Medium 
 -Germination medium, .2gm/L IBA 
 
-Shoot Induction Medium 
 -Same as Callus Induction Medium 
 
-Transformant Selection Medium 
 Same as shoot outgrowth Medium, 10g/L sucrose. 
 
 
Transformation: 
 
Dwarf blue kale was obtained from a standard online gardening website. It was chosen 
specifically for its smaller size. Kale seeds were surfaced sterilized in bleach containing 
6.5% sodium hypochlorite and shaken vigorously for 20 min. The seeds were then rinsed 
five times with sterile distilled water and placed onto germination medium. Cotyledons 
and hypocotyls sections were cut from four day old germinated seedlings and placed on 
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callus induction medium. The Hypocotyls and cotyledons were dipped in A. tumefaciens 
suspension OD650 = .05 containing pBTPADSTPFPS. After exposure to the bacteria for 
1min the explants were immediately placed onto basal media with infected edge into the 
media, hypocotyls were placed vertically and co-cultivated with the bacteria for 2 days 
and then transferred to callus induction medium containing 500mg/L carbenicillin. From 
this point on all media contains 500mg/L of carbenicillin. 7 days later explants were 
transferred to shoot induction media containing carbenicillin and 25mg/L kanamycin. 
These explants were transferred to fresh medium every two weeks. When green shoots 
formed they were placed into shoot outgrowth medium containing carbenicillin and 
25mg/L kanamycin. The shoots that remained green on this medium were then 
transferred to transformant selection medium containing 50mg/L. The shoots that 
remained green were finally transferred to root induction medium.  
 
RNA extraction: 
 
A leaf was cut off the kale and massed at .1g. This was frozen with liquid nitrogen, 
ground up and vortexed with .5mL cold PureLink
TM
 plant RNA reagent until resuspended. 
The tube was incubated horizontally at room temperature for 5min before centrifuging at 
12,000g in a microcentrifuge for 2 minutes at room temperature. After transferring the 
supernatant to a new RNase-free tube .1mL of 5M NaCl was added to the clarified extract 
and the solution was mixed by tapping. .3mL of chloroform was added to the sample and 
mixed thoroughly by inverting the tube. The tube was again centrifuged at 12,000 x g for 
20min at 4
o
C, and the upper aqueous phase was transferred again to an RNase-free tube. 
To this there was an equal volume of isopropyl alcohol added. The solution was vortexed 
briefly and allowed to sit at room temperature for 10 minutes before being centrifuged at 
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12,000 x g for 20 minutes at 4
o
C. The supernatant was aspirated out carefully and 1mL of 
75% ethanol was added to the pellet. The solution was centrifuged at 12,000 x g for 1 
min at room temperature and the supernatant was again removed by aspiration. 20µL of 
RNase-free water was added to the RNA pellet and the pellet was resuspended and kept 
stored at -80
o
C. 
 
Reverse transcription: 
A mastermix was prepared using 4µL 10 buffer RT, 4 µL dNTP mix (5 mM of each 
dNTP), 4 µL Oligo-dT primer, 2 µL RNase inhibitor, 2 µL Omniscript Reverse 
Transcriptase and RNase free water to a final volume of 40 µL after the template would 
be added. The template RNA was added to individual tubes containing the master mix, 
vortexed briefly, centrifuged briefly to collect drops on the side of the tube and allowed 
to incubate at 37
o
C for 60 min. 
 
BAP: 
 
Dissolve in 1N NaOH and bring to volume with water. 
 
Rifampicin: 
Dissolve in methanol. 
 
 
 
RESULTS: 
 
Kale seeds were surface sterilized and germinated to produce hypocotyls and cotyledons 
for subsequent transformations. Seeds had a germination rate of 100% for the first five 
trials. 40 seeds were used for the first second and sixth trials, 30 were used in the third 
forth and fifth. The sixth trial using 40 seeds had a germination rate of 77% most likely 
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due to an overexposure to the sterilizing agent sodium hypochlorite. The transformation 
was performed with the cells containing A. tumefaciens containing the plasmid 
pBTPADSTPFPS for the first trial. The second and third trial utilized A. tumefaciens with 
pGGFPFAC2A The fourth and fifth trial utilized A. rhizogenes containing the plasmid 
pGGFPFAC2A. The sixth trial contains A. rhizogenes without a plasmid insertion. The 
first three trials had successful growths with an approximate transformation rate of 18% 
(on average 7 explants per trial survived on kanamycin media). For the first 4 trials 
hypocotyl lengths were 1cm. Better results were noted with smaller hypocotyls in the 
fifth and sixth trials, about a 15% transformation rate, so the hypocotyl size used was 
reduced to 3-5mm thus allowing 2 hypocotyl segments per seed to be used.  
On the second and third attempts there were problems with overgrowth of bacteria. 
When the explants were plated on media containing carbenicillin there was still a large 
amount of bacterial growth. When this growth was noticed the explants were then rinsed 
in MS media and transferred to new media containing carbenicillin. The bacterial growth 
persisted and resulted in the explants turning white and dying. The company that 
produced the carbenicillin was contacted and we were informed it was a lower potency 
than their normal product, about 57% the expected potency.  
A plant that was living on high kanamycin media from both the first and second 
trials were chosen and a leaf was taken from each (about 100mg of plant matter). The 
RNA was extracted using the method described in the materials and methods section. 
Using this RNA a reverse transcription was performed and the product was amplified in a 
PCR machine. The results of the PCR were negative for ADS expression. 
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Conclusions: 
 
When first starting the series of experiments described in the earlier sections a hypocotyl 
length of approximately 1-1.5cm was used. Starting at the fourth trial due to smaller 
cotelydons and a lack to infect with bacteria smaller hypocotyl sections were utilized. It 
was found that these sections appear to have a better survival rate by about 25%. These 
numbers are approximate as since bacterial overgrowth interfered with the experiment.  
 
The results of the transformations are still inconclusive. RT-PCRs were performed on 
leaves from plants from two different germination series, the first and the second. Both of 
these series show resistance to high kanamycin media, however the RT-PCR did not 
confirm the presence of our genes, specifically ADS. The first germination series was 
infected with A. tumefaciens containing a plasmid with transit peptides. These cells had 
the desired plasmid inserted along with a resistance to kanamycin to provide as a 
selective marker.  The second germination series was infected using A. tumefaciens 
containing 2A sections of the foot and mouth disease virus under a single 35S promoter. 
The 2A section allows for ribosomal skipping and results in the uncatalyzed cleaving of 
proteins after being expressed in the ribosome. The polycistronic plasmid would mean 
that if ADS is expressed the entirety of the plasmid was being expressed at the same level. 
The third and fourth series were infected with A. rhizogenes. There was overgrowth on 
both of these series and they never survived to the point of being able to test for the 
presence of expression. The carbenicillin used during the third and fourth series was 
found to be of a lower potency (57%) than what it should have been. This and the 
difference in bacteria could have both been reasons for the overgrowth observed.  
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